Fluoroquinolone resistance during 2000-2005 : An observational study

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Ryan, Richard J ^a   Lindsell, Chris ^a   Sheehan, Paul ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; CORRELATION COEFFICIENT; ENTEROBACTER AEROGENES; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBSERVATIONAL STUDY; WORLD HEALTH ORGANIZATION; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; DRUG EFFECT; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HOSPITAL PHARMACY; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; ENTEROBACTER AEROGENES; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHARMACY SERVICE, HOSPITAL; PNEUMONIA, BACTERIAL; QUINOLINES;

EID: 45449107016     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-71     Document Type: Article

References (15)

1. French GL Clinical impact and relevance of antibiotic resistance Advanced Drug Delivery Reviews 2005, 57:1514-1527. 10.1016/ j.addr.2005.04.005 15978698
2. Kollef MH Bench-to-bedside review: Antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit Crit Care 2005, 9(5):459-64. 1297604 16277734 10.1186/cc3757
3. Naber KG Which fluoroquinolones are suitable for treatment of urinary tract infections? International Journal of Antimicrobial Agents 2001, 17:331-341. 10.1016/S0924-8579(00)00362-9 11295418
4. WHO Collaborating Centre for Drug Statistics Methodology http://www.whocc.no/atcddd/
5. Fogarty C Torres A Choudri S Haverstock D Herrington J Ambler J Efficacy of Moxifloxacin for treatment of penicillin-, macrolide-, and multidrug resistant Streptococcus pneumonia in community-acquired pneumonia J Clin Pract 2005, 59(11):1253-1259. 10.1111/j.1368-5031.2005.00699.x
6. Simoens S Verhaegen J Laekeman G Peetermans WE Treating respiratory tract infections in ambulatory care in Belgium: Fluoroquiniolone consumption and resistance development International Journal of Antimicrobial Agents 2005, 26:62-68 10.1016/j.ijantimicag.2005.03.010 15963695
7. Saravolatz L Manzor O Pawlak J Belian B Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptoccous pneumoniae International Journal of Antimicrobial Agents 2005, 26:81-84. 10.1016/ j.ijantimicag.2005.03.004 15951159
8. Malangoni MA Song J Herrington J Choudrhri S Pertel P Randomized Controlled Trial of Moxifloxacin Compared With Piperacillin-Tazobactam and Amoxicillin-Clavulanate for the Treatment of Complicated Intra-abdominal Infections Annals of Surgery 2006, 244(2):204-11. 1602153 16858182 10.1097/01.sla.0000230024.84190.a8
9. Miravitlles M Moxifloxacin in respiratory tract infections Expert Opinion on Pharmacotherapy 2005, 6(2):283-93. 10.1517/14656566.6.2.283 15757424
10. Stein GE Schooley S Urinary concentrations and bactericidal activities of newer fluoroquinolones in health volunteers International Journal of Antimicrobial Agents 2004, 24:168-172. 10.1016/j.ijantimicag.2004.01.013 15288316
11. Rosen DA Hooton TM Stamm WE Humphrey PA Hultgren SJ Detection of Intracellular Bacterial Communities in Human Urinary Tract Infection PLOS Medicine 2007, 4(12):1949-58. 10.1371/journal.pmed.0040329
12. Leigh DA Tait S Walsh B Antibacterial activity of Lomefloxacin Journal of Antimicrobial Chemotherapy 1991, 27:589-98. 10.1093/jac/27.5.589 1885417
13. Jacoby GA Mechanisms of Resistance to Quinolones Clinical Infectious Diseases 2005, 41(Suppl 1):120-6. 10.1086/428052
14. von Baum H Bommer M Kern WV MArre R Döhner H Kern P Reuter S Moxifloxacin prophylaxis in neutropenic patients Journal of Antimicrobial Chemotherapy 2006, 58:891-4. 10.1093/jac/dkl320 16880172
15. Joris JJ Leur Van De PM Vollar EJ Janssen AHJM Dofferhoff ASM Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance Scandinavian Journal of Infections Disease 1997, 29:297-300.